Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

J&J Q3 Net Profit Slips; Revises 2012 Adj. EPS View - Quick Facts

RELATED NEWS
Trade JNJ now with 

Johnson & Johnson (JNJ: Quote) posted a decline in third-quarter net earnings attributable to the company to $2.97 billion, or $1.05 per share, from $3.20 billion, or $1.15 per share a year before.

However, excluding items, quarterly adjusted earnings totaled $3.52 billion, or $1.25 per share, higher than $3.44 billion, or $1.24 per share last year. On average, 16 analysts polled by Thomson Reuters expected earnings per share of $1.21 for the quarter. Analysts' estimates typically exclude one-time items.

Sales to customers were $17.1 billion for the 2012 third quarter, up 6.5% as compared with last year's $16.0 billion, while 13 analysts estimated revenues of $16.95 billion for the quarter. Operational results went up 10.8% and the negative impact of currency was 4.3%. Domestic sales increased 13.4%. International sales rose by 1.4%, reflecting operational growth of 8.9% and a negative currency impact of 7.5%.

For full year 2012, the company now sees earnings of $5.05 - $5.10 per share, excluding the impact of special items. Twenty analysts project annual earnings of $5.06 per share.

Click here to receive FREE breaking news email alerts for Johnson & Johnson and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Swiss drug maker Roche Holding said a late-stage trial of its breast cancer drug Kadcyla did not provide superior results compared with an existing therapy. FCA US, until recently known as Chrysler, said Friday it is recalling 257,000 Dodge Ram pickups. The auto maker says the rear axle pinion nut on certain model year 2005 Dodge Ram 1500 trucks may loosen due to an undersized spline on the pinion gear. If the pinion nut loosens, the rear axle may... This medical device company has a very impressive track record of growing business over the past decade. increasing sales from $490.2 million in 2004 to $1.72 billion this year. The Silicone Hydrogel daily disposable lens portfolio constitutes a major avenue for growth.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.